



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: PRTA

Last Trade:	56.24
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	40.58 - 69.53
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 15, 2017

[Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting](#)

Aug 8, 2017

[Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update](#)

Aug 1, 2017

[Prothena to Report Second Quarter 2017 Financial Results on August 8](#)

Jul 5, 2017

[Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease](#)

Jun 12, 2017

[Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 27, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 2, 2016

[Quarterly Report \(10-Q\)](#)